Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPoolbeg Pharma Share News (POLB)

Share Price Information for Poolbeg Pharma (POLB)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12.15
Bid: 12.10
Ask: 12.20
Change: -0.20 (-1.62%)
Spread: 0.10 (0.826%)
Open: 12.35
High: 12.35
Low: 12.05
Prev. Close: 12.35
POLB Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

9 Jan 2023 14:14

Poolbeg Pharma says initial POLB 001 data shows positive response

(Alliance News) - Poolbeg Pharma PLC on Monday said initial data analysis in its POLB 001 LPS challenge trial indicated a clear anti-inflammatory response.

Read more
21 Dec 2022 19:20

TRADING UPDATES: Atlantis Japan underperforms; Bellevue lowers payout

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

Read more
21 Dec 2022 13:37

Poolbeg identifies new drug candidates with OneThree

(Sharecast News) - Biopharmaceutical company Poolbeg Pharma has successfully identified potential new drug candidates from its respiratory syncytial virus (RSV) artificial intelligence (AI) programme with OneThree Biotech, it announced on Wednesday.

Read more
14 Dec 2022 21:54

TRADING UPDATES: Poolbeg acquires license; Afentra expects PSA delay

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

Read more
14 Dec 2022 16:14

Poolbeg secures exclusive licence to possible obesity drug tech

(Sharecast News) - Infectious disease-focussed biopharmaceutical company Poolbeg Pharma has acquired an exclusive licence from AnaBio sister company InsuCaps, it announced on Wednesday, to use its patented microencapsulation and nanoencapsulation oral delivery technologies in metabolic syndrome-related diseases, including obesity, pre-diabetes and diabetes.

Read more
2 Dec 2022 19:33

TRADING UPDATES: Time Out eyes Riyadh; MTI Wireless wins deal

(Alliance News) - The following is a round-up of updates by London-listed companies, issued this week and not separately reported by Alliance News:

Read more
15 Nov 2022 17:25

Poolbeg Pharma wins funding for oral vaccine development

(Alliance News) - Poolbeg Pharma PLC on Tuesday said it has received funding from the Irish Government to improve the manufacturing, distribution and administration of its oral vaccines.

Read more
8 Nov 2022 13:06

Poolbeg announces 'breakthrough' in AI drug target programme

(Sharecast News) - Infectious disease pharmaceutical developer Poolbeg Pharma announced a "significant breakthrough" in its artificial intelligence (AI) programme with partner OneThree Biotech on Tuesday, through the discovery of novel drug targets for the treatment of respiratory syncytial virus (RSV).

Read more
8 Nov 2022 12:18

IN BRIEF: Poolbeg makes "significant breakthrough" in AI programme

Poolbeg Pharma PLC - London-based clinical stage infectious disease pharmaceutical company - Announces "significant breakthrough" in its artificial intelligence programme with its partner OneThree Biotech Inc, a New York-based drug discovery-focused firm. Says breakthrough is the discovery of novel drug targets for the treatment of respiratory syncytial virus. The identification of these targets allow for the final stages of the programme to start, Poolbeg explains. This will involve the identification of small molecule inhibitors to treat RSV infections. The team is "particularly excited", the firm says, as these include a range of targets for which there are known drugs with existing Phase I safety and tolerability data. Results are expected before the end of 2022.

Read more
4 Oct 2022 14:14

Poolbeg Pharma upbeat on US patent application progress

(Sharecast News) - Infectious disease pharmaceutical company Poolbeg Pharma updated the market on its intellectual property (IP) position around 'POLB 001' on Tuesday, which it described as a small molecule immunomodulator for the treatment of severe influenza.

Read more
4 Oct 2022 10:14

Poolbeg expects formal patent grant soon to treat hypercytokinemia

(Alliance News) - Poolbeg Pharma PLC on Tuesday said that the US Patent & Trademarks Office has indicated that its patent application concerning the use of POLB 001 and its homologues for the treatment of hypercytokinemia is allowable.

Read more
4 Oct 2022 08:46

LONDON MARKET OPEN: Stocks rise as market sentiment recovers

(Alliance News) - Stock prices in London opened sharply higher on Tuesday, lifted by more positive market sentiment following the UK government's tax U-turn, as well as some positive trading updates.

Read more
4 Oct 2022 07:52

LONDON BRIEFING: Pound, oil, gold up; Truss vows fiscal responsibility

(Alliance News) - Stocks in London are called higher on Tuesday, as the market watches closely for further clues regarding the UK's economic direction.

Read more
27 Sep 2022 06:59

IN BRIEF: Poolbeg Pharma teams up for Melioidosis vaccine

Poolbeg Pharma PLC - London-based pharmaceutical company - On Wednesday reported it a signed an in-license agreement for the development of a Melioidosis vaccine candidate with University College Dublin. Melioidosis is an infectious disease spread by a bacterium in contaminated soil or water. It has a minimum fatality rate of around 10% and no vaccine for the disease exists. Poolbeg's late preclinical stage vaccine candidate has the name POLB 003. It is being developed following several years of research.

Read more
21 Sep 2022 16:18

Poolbeg inks exclusive deal for melioidosis vaccine candidate

(Sharecast News) - Clinical-stage infectious disease pharmaceutical company Poolbeg Pharma has signed an exclusive licence agreement with University College Dublin (UCD), it announced on Wednesday, for a late preclinical-stage vaccine candidate for melioidosis.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.